25 August 2025

---

Oral Genome Partners with Henry Schein Nationwide

---

Oral Genome, a leading innovator in salivary testing, today announced a strategic partnership with Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners. This collaboration aims to bring Oral Genome’s cutting-edge point-of-care saliva testing to dental and medical practices nationwide, advancing the integration of oral and systemic healthcare.

Oral Genome’s saliva test kits are run at the point of care and deliver results in 15 minutes. The saliva test and software application analyze key biomarkers in saliva that offer a real-time look at a patient’s oral and overall health. By partnering with Henry Schein’s expansive network, this technology will empower dental professionals to offer valuable insights into oral and systemic health issues chairside, fostering early and stronger patient-provider relationships.

“We’re thrilled to join forces with Henry Schein to support providers bridging the gap between dental and medical care,” said Dr. Tina Saw, CEO of Oral Genome. “Our point-of-care testing equips practitioners with actionable insights, transforming routine visits into opportunities for whole-health advocacy.”

“Henry Schein is committed to bringing advanced solutions that enhance patient outcomes to our customers,” said Dirk Benson, President of Henry Schein’s U.S. Distribution Group. “Expanded point-of-care testing offerings align with our mission to advance prevention and wellness through systemic health models, and Oral Genome offers dentists and physicians a powerful tool to elevate care.”

The partnership will roll out through Henry Schein’s distribution channels, targeting dental practices, community health clinics, and medical offices seeking new preventive care techniques. This initiative underscores both companies’ dedication to advancing healthcare through technology and collaboration.

About Oral Genome

Oral Genome is a biotechnology company pioneering the future of preventive health through point-of-care salivary testing. Built by a team of dentists, scientists, and health technologists, the company’s mobile-compatible test kits deliver clinical-grade results in under 15 minutes—without the need for lab processing.

By analyzing key salivary biomarkers linked to conditions such as dental caries, periodontal disease, and diabetes, Oral Genome enables providers to identify oral-systemic risks early, drive timely interventions, and personalize patient care. Its platform bridges the gap between dental and medical care, supports value-based models, and improves access to prevention—especially for underserved populations.

Invested in by the American Dental Association and actively used by health systems, DSOs, and state agencies, Oral Genome is redefining how oral and systemic health are connected—one saliva test at a time. 

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.    

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

Source: www.henryschein.com